Company news

Journey Medical Corporation news in 2024

Journey Medical Corporation's news releases, calls and decks from 2024, newest first.

View company

Journey Medical Corporation Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

November 11, 2024

Journey Medical Corporation Announces U.S. FDA Approval of Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the Treatment of Rosacea

November 3, 2024

Journey Medical Corporation Announces DFD-29 Data Presented at 44th Fall Clinical Dermatology Conference

October 24, 2024

Journey Medical Corporation to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference

October 2, 2024

Journey Medical Corporation to Participate in the Lake Street Capital Markets 8th Annual Best Ideas Growth (BIG) Conference

September 8, 2024

Journey Medical Corporation to Present at the H.C. Wainwright 26th Annual Global Investment Conference

September 3, 2024

Journey Medical Corporation Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights

August 11, 2024

Journey Medical Corporation to Announce Second Quarter 2024 Financial Results on August 12, 2024

August 5, 2024

SWK Holdings Highlights Recent Achievements and Provides Portfolio Update

July 16, 2024

Journey Medical Corporation Appoints Michael C. Pearce to Board of Directors

July 10, 2024

Journey Medical Corporation to Participate in the Alliance Global Partners’ (A.G.P.) Virtual Healthcare Company Showcase

May 14, 2024

Journey Medical Corporation Reports First Quarter 2024 Financial Results and Recent Corporate Highlights

May 12, 2024

Journey Medical Corporation to Announce First Quarter 2024 Financial Results on May 13, 2024

May 6, 2024

Journey Medical Corporation Appoints Joseph Benesch as Chief Financial Officer

April 30, 2024

Journey Medical Corporation to Present at the Planet MicroCap Showcase: Vegas 2024

April 24, 2024

Journey Medical Corporation Reports Full-Year 2023 Financial Results and Recent Corporate Highlights

March 20, 2024

Journey Medical Corporation Announces U.S. FDA Acceptance of New Drug Application for DFD-29 for the Treatment of Rosacea

March 17, 2024

Journey Medical Corporation to Announce Year End 2023 Financial Results on March 21, 2024

March 14, 2024

Journey Medical Corporation to Participate in the 36th Annual ROTH Conference

March 12, 2024

Journey Medical Corporation Announces Presentation of Data from Phase 1 Clinical Trial Assessing the Impact of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) on Microbial Flora of Healthy Adults at 2024 AAD Annual Meeting

March 10, 2024

Journey Medical Corporation Submits New Drug Application to FDA for DFD-29 to Treat Rosacea

January 4, 2024

Journey Medical Corporation Secures Credit Facility with SWK Holdings for up to $20 Million

January 1, 2024

Calls in 2024